Long non-coding RNA RP11J20.1 predicts a poor prognosis and promotes hepatocellular carcinoma tumorigenesis
详细信息 查看官网全文
- 英文论文题名：Long non-coding RNA RP11J20.1 predicts a poor prognosis and promotes hepatocellular carcinoma tumorigenesis
- 论文作者：Penghui Yang ; Sijie Cheng ; Chengcai Lai ; Jin Yan ; Peirui Zhang ; Shaogeng Zhang ; Xiliang Wang
- 英文论文作者：Penghui Yang ; Sijie Cheng ; Chengcai Lai ; Jin Yan ; Peirui Zhang ; Shaogeng Zhang ; Xiliang Wang ; Beijing 302 Hospital ; Beijing Institute of Microbiology and Epidemiology ; State Key Laboratory of Pathogen and Biosecurity
- 年：2016
- 作者机构：Beijing 302 Hospital;Beijing Institute of Microbiology and Epidemiology,State Key Laboratory of Pathogen and Biosecurity;
- 英文论文关键词：lncRNA ; hepatocellular carcinoma ; RP11J20 ; 1 ; qRT-PCR
- 会议召开时间：2016-11-04
- 会议录名称：第十一届全国免疫学学术大会摘要汇编
- 英文会议录名称：Abstracts of 2016 CSI Congress on Immunology
- 语种：英文
- 分类号：R735.7
- 学会代码：IGMD
- 会议名称：第十一届全国免疫学学术大会
- 会议地点：中国安徽合肥
- 主办单位：中国免疫学会
- 学会名称：中国免疫学会
- 页数：2
- 文件大小：1336k
- 原文格式：D
- 会议级别：全国
摘要
Hepatocellular carcinoma(HCC) is a leading cause of cancer mortality worldwide. Despite progress in the diagnosis and treatment of HCC, its prognosis still remains unfavorable. In accumulating studies, long non-coding RNAs(lncRNAs) are emerging as vital players in tumorigenesis and cancer progression. However, the molecular mechanisms and clinical significance of lncRNAs in HCC remain largely elusive. In this study, we analyzed lncRNA microarray expressionprofiles of tumor samples and its matched adjacent tissue samples from 10 HCC patients and found that the expression of RP11J20.1 in HCC tissues is makedly lower than adjacent tissues. Expression of RP11J20.1 was also remarkably downregulated in 112 HCC tissues and cell lines by qRT-PCR. Low RP11J20.1 expression was correlated with alphafetoprotein(AFP) level, tumor size and microvascular invasion. Kaplan-Meier survival analysis demonstrated that low RP11J20.1 expression predicts poor prognosis of HCC patients. Gain-of-function and loss-of-function experiments showed that RP11J20.1 promotes HCC cells proliferation, cell cycle progression, and inhibits HCC cells apoptosis. Further experiments revealed that RP11J20.1 promotes HCC cells proliferation through inhibiting STAT1 genes expression. Collectively, our results demonstrated the clinical prognostic significance and roles of RP11J20.1 in HCC, and suggested that RP11J20.1 may be considered as a prognostic biomarker and therapeutic target for HCC.
Hepatocellular carcinoma(HCC) is a leading cause of cancer mortality worldwide. Despite progress in the diagnosis and treatment of HCC, its prognosis still remains unfavorable. In accumulating studies, long non-coding RNAs(lncRNAs) are emerging as vital players in tumorigenesis and cancer progression. However, the molecular mechanisms and clinical significance of lncRNAs in HCC remain largely elusive. In this study, we analyzed lncRNA microarray expressionprofiles of tumor samples and its matched adjacent tissue samples from 10 HCC patients and found that the expression of RP11J20.1 in HCC tissues is makedly lower than adjacent tissues. Expression of RP11J20.1 was also remarkably downregulated in 112 HCC tissues and cell lines by qRT-PCR. Low RP11J20.1 expression was correlated with alphafetoprotein(AFP) level, tumor size and microvascular invasion. Kaplan-Meier survival analysis demonstrated that low RP11J20.1 expression predicts poor prognosis of HCC patients. Gain-of-function and loss-of-function experiments showed that RP11J20.1 promotes HCC cells proliferation, cell cycle progression, and inhibits HCC cells apoptosis. Further experiments revealed that RP11J20.1 promotes HCC cells proliferation through inhibiting STAT1 genes expression. Collectively, our results demonstrated the clinical prognostic significance and roles of RP11J20.1 in HCC, and suggested that RP11J20.1 may be considered as a prognostic biomarker and therapeutic target for HCC.
Hepatocellular carcinoma(HCC) is a leading cause of cancer mortality worldwide. Despite progress in the diagnosis and treatment of HCC, its prognosis still remains unfavorable. In accumulating studies, long non-coding RNAs(lncRNAs) are emerging as vital players in tumorigenesis and cancer progression. However, the molecular mechanisms and clinical significance of lncRNAs in HCC remain largely elusive. In this study, we analyzed lncRNA microarray expressionprofiles of tumor samples and its matched adjacent tissue samples from 10 HCC patients and found that the expression of RP11J20.1 in HCC tissues is makedly lower than adjacent tissues. Expression of RP11J20.1 was also remarkably downregulated in 112 HCC tissues and cell lines by qRT-PCR. Low RP11J20.1 expression was correlated with alphafetoprotein(AFP) level, tumor size and microvascular invasion. Kaplan-Meier survival analysis demonstrated that low RP11J20.1 expression predicts poor prognosis of HCC patients. Gain-of-function and loss-of-function experiments showed that RP11J20.1 promotes HCC cells proliferation, cell cycle progression, and inhibits HCC cells apoptosis. Further experiments revealed that RP11J20.1 promotes HCC cells proliferation through inhibiting STAT1 genes expression. Collectively, our results demonstrated the clinical prognostic significance and roles of RP11J20.1 in HCC, and suggested that RP11J20.1 may be considered as a prognostic biomarker and therapeutic target for HCC.
引文